MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines ; volume:11 ; number:1 ; day:30 ; month:5 ; year:2011 ; pages:1-11 ; date:12.2011
BMC cancer ; 11, Heft 1 (30.5.2011), 1-11, 12.2011
- Urheber
-
Ohnstad, Hege O.
- Beteiligte Personen und Organisationen
-
Paulsen, Erik B.
Noordhuis, Paul
Berg, Marianne
Lothe, Ragnhild A.
Vassilev, Lyubomir T.
Myklebost, Ola
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-11-211
- URN
-
urn:nbn:de:1111-2016030363100
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ohnstad, Hege O.
- Paulsen, Erik B.
- Noordhuis, Paul
- Berg, Marianne
- Lothe, Ragnhild A.
- Vassilev, Lyubomir T.
- Myklebost, Ola
- SpringerLink (Online service)
Ähnliche Objekte (12)
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
Targeting MDM2, the antagonist of the tumor suppressor p53
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Acid affairs in anti-tumour immunity
The MDM2 gene family
Antagonist
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
Targeting MDM2, the antagonist of the tumor suppressor p53
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Acid affairs in anti-tumour immunity
The MDM2 gene family
Antagonist
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells
Targeting MDM2, the antagonist of the tumor suppressor p53
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response
ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia
The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Acid affairs in anti-tumour immunity
The MDM2 gene family
Antagonist